Page 2 - Daniel Yu News Today

(Bloomberg) -- Grifols SA sued Gotham City Research over a report alleging the company has overstated profit and misstated its accounting.Most Read from BloombergPutin Sends US Signal on Ukraine Talks, Seeing War AdvantageOne of World’s Richest Doctors Sees Fortune Surge to $12 BillionFed’s Preferred Inflation Gauge Cools on Robust SpendingJPMorgan Shuffles Top Managers as Jamie Dimon Prepares SuccessorsUN Court Tells Israel to Protect Gazans, Avoids Cease-FireGotham City Research,...

Spanish pharmaceutical company Grifols said on Friday it had a filed a lawsuit in New York against the founder of short-seller fund Gotham City Research, Daniel Yu, and his company, seeking damages...

01/26/2024 - 19:38 | Updated: 01/26/2024 - 19:40 This is a reading test of Vilaweb articles in a synthetic voice, which will soon be available to

Eisgruber will discuss the letter and invite questions at two upcoming open meetings for the campus community.

The Catalan pharmaceutical company Grifols wanted to make it clear this Sunday that the devastating report from the bear fund Gotham City Research, which

Pharmaceutical company Grifols (GRFS) faced a significant setback following the release of a report by Gotham City Research. The report accused the firm of serious accounting manipulations, raising concerns about its stock value.

Spanish blood plasma company Grifols saw its shares plunge more than 40% at one point on Tuesday after hedge fund Gotham City Research questioned the...

Shares of the Spanish drugmaker drop 42% after hedge fund questions debt ratios

MADRID/BARCELONA (Reuters) -Shares in Grifols fell by 30% on Tuesday, wiping nearly $3 billion off its market value, after hedge fund Gotham City Research questioned its accounting, prompting the Spanish drugmaker to "categorically" deny any wrongdoing. Gotham questioned Grifols' reported debt and earnings before interest, taxes, depreciation and amortisation (EBITDA), and leverage ratio of 6.7 times. It said the leverage ratio is close to 10 to 13 times EBITDA.

Wasoko and MaxAB will trim roughly 10% of the combined workforce of both companies as merger talks advance, TechCabal has learned